Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BEAM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.16B
- EPS (TTM)
- -$0.87
- Dividend yield
- None
- 52-week range
- 20.44 – 38.26
- Day range
- 20.54 – 22.10
- Volume / Avg
- 3.88M / 2.04M
- Beta
- —
- Shares outstanding
- 103.50M
52-week range
BEAM stock today
Shares of Beam Therapeutics (BEAM) finished lower on Nov 20 at $20.90, a drop of 0.19% or $0.04 per share, versus the S&P 500's 3.70% decline. Shares are 45.4% below their 52-week high of $38.26, set on Jul 7, 2026 and 2.3% above the 52-week low of $20.44, near the bottom of the past year's range. BEAM is down 24.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.9%.
Beam Therapeutics has posted a net loss over the last twelve months (EPS of -$0.87), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Beam Therapeutics
Company profileBeam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. John M. Evans M.B.A.
- Headquarters
- Cambridge, MA
- Employees
- 557
- IPO year
- 2020
- Website
- beamtx.com
Financial highlights
Full financialsIn fiscal 2025, Beam Therapeutics generated $139.7 million in revenue, up 120.0% from fiscal 2024. Beam Therapeutics reported a net loss of $80.0 million, compared with a loss of $376.7 million a year earlier. Operating margin was -274.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $139.74M | $63.52M | $377.71M | $60.92M | $51.84M |
| Growth | +120.01% | -83.18% | +520.01% | +17.51% | +215916.67% |
| Net income | $-79.99M | $-376.74M | $-132.53M | $-289.09M | $-370.64M |
| EPS (diluted) | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$49.85+138.52%
- Strong buy 1
- Buy 12
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-1.28 vs $-1.17
- Surprise
- -9.40%
BEAM news
All BEAM news- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike DealsNasdaqAMGN, ARGX, AZN, BEAM
- Beam Therapeutics Inc. Reports Third Quarter 2026 Financial Results and Clinical ProgressNasdaq
- Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue EstimatesNasdaqBEAM, TWST
- Beam Therapeutics GAAP EPS of -$1.28 misses by $0.13, revenue of $0.31MSeeking Alpha
- Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing PortfolioGlobeNewswire
- 3 Promising Genomics Stocks to Add to Your Portfolio NowNasdaqILMN, QURE, TXG, BEAM
- Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual CongressGlobeNewswire
- Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?NasdaqBEAM, LLY, PFE, ARKG
Beam Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs BEAM |
| COAGHemab Therapeutics Holdings Inc. | 39.29 | -1.43% | $1.84B | vs BEAM |
| REPLReplimune Group Inc. | 19.07 | -0.83% | $1.81B | vs BEAM |
| LYCALycia Therapeutics Inc. | 33.07 | +4.09% | $1.72B | vs BEAM |
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs BEAM |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs BEAM |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs BEAM |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs BEAM |
Indexes, lists and sector
Beam Therapeutics stock FAQ
What is Beam Therapeutics's stock price today?
BEAM last traded at $20.90 as of Nov 20, 4:00 PM EST, down 0.19% on the day. Prices are delayed at least 15 minutes.
Who is Beam Therapeutics's CEO?
Mr. John M. Evans M.B.A. is the chief executive officer of Beam Therapeutics Inc., which has about 557 employees.
What is the BEAM 52-week high?
The 52-week high for BEAM is $38.26 and the 52-week low is $20.44. The stock is currently 45.4% below its high.